Clinical Trials Browser

Phase 1 × OTHER × Multiple Sclerosis × Clear all

NCT07526493 2026-05-12

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT07085676 2026-05-06

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Phase 1 Recruiting

120 enrolled

Arthritis, Rheumatoid, Lupus Erythematosus, Systemic, Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Scleroderma, Systemic, Antiphospholipid Syndrome, Multiple Sclerosis, Chronic Progressive

NCT06249438 2025-07-25

CAR-AID

Phase 1 Recruiting

30 enrolled

Lupus Erythematosus, Systemic, Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Scleroderma, Systemic

NCT06869278 2025-06-11

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

Phase 1 Recruiting

37 enrolled

Multiple Sclerosis, Myasthenia Gravis, Recurrence

NCT03656627 2023-02-15

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

Phase 1 Terminated

7 enrolled

Thoracic

Arthritis, Rheumatoid, Autoimmune Diseases, Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative, Crohn Disease, Lupus Erythematosus, Systemic, Multiple Sclerosis, Polymyalgia Rheumatica, Psoriasis, Giant Cell Arteritis